Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- 7 days ago
- 1 min read
09/08/2026
US FDA Fast Track Designation for FAP‑targeted radionuclide conjugate GPN01530-2 (Ref)
Grand Pharmaceutical Group Limited announced that its investigational radionuclide-drug conjugate GPN01530-2, targeting fibroblast activating protein (FAP), has received Fast Track Designation from the US FDA
Comments